/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-11-04 23:42:442020-11-04 23:42:44CALCIMEDICA ANNOUNCES THAT FDA HAS STRONGLY RECOMMENDED MOVING TO A BLINDED PLACEBO-CONTROLLED TRIAL WITH AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-11-04 23:41:042020-11-04 23:41:04CALCIMEDICA APPOINTS ROBERT N. WILSON AS CO-CHAIRMAN OF THE BOARD OF DIRECTORS AND ERIC W. ROBERTS AS VICE CHAIRMAN
Link to Full Article MARINA DEL REY, Calif., Oct. 29, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today issued the following letter to shareholders. The letter has been made available to all existing shareholders with the Proxy for the […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-10-29 03:11:332020-11-04 23:31:04Armata Pharmaceuticals Issues Letter to Shareholders
Link to Full Article A recent study from the University of Birmingham has shown that the Congenica platform demonstrated superior performance in identifying the genetic causes of platelet-related bleeding disorders [1]. Whole Exome Sequencing in combination with deep platelet phenotyping has been used in an earlier study (Genotyping and Phenotyping of Platelets, UK-GAPP) to identify pathogenic genetic […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-10-27 03:19:192020-10-30 03:20:23Congenica enhances the detection of inherited platelet disorders
Link to Full Article Appointment adds extensive expertise in the development of anti-infectives, including bacteriophage therapy to treat P. aeruginosa infections in cystic fibrosis patients MARINA DEL REY, Calif., Oct. 26, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-10-26 03:10:022020-10-30 03:11:13Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
Link to Full Article FundamentalVR launches full commercial ophthalmology capability BOSTON – October 20, 2020 – FundamentalVR, global pioneers in immersive VR surgical skills training and skills data analytics, today announced the expansion of its surgical specialty capabilities with the addition of ophthalmology. Powered by the company’s patented HapticVRTM technology architecture that mimics the physical cues of […]
Link to Full Article Adds ready-to-administer injectable product to companies’ existing partnership London and Cambridge, October 20, 2020 – Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into a new exclusive agreement to co-develop […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-10-20 03:05:082020-10-30 03:06:19HIKMA AND ARECOR EXPAND COLLABORATION WITH NEW AGREEMENT TO DEVELOP AND COMMERCIALISE READY-TO-ADMINISTER MEDICINE
Link to Full Article Upcoming study, to be known as “SWARM-P.a.,” is believed to be first FDA cleared, controlled clinical trial to evaluate a multiple phage-based mixture as a therapeutic candidate in Cystic Fibrosis patients MARINA DEL REY, Calif., Oct. 15, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-10-15 03:07:172020-10-30 03:08:55Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections
Link to Full Article 101 patients recruited in Phase 2b clinical study of lead asset XF-73 for the prevention of postsurgical infections Recruitment on track to complete by year-end and report results in Q1 2021 Brighton, United Kingdom – 12 October 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the […]
Link to Full Article Cambridge, United Kingdom – 22 September 2020 – Congenica has launched a new module for its genomic analysis platform that will accelerate research into the relationship between an individual’s genomic variation and COVID-19 susceptibility, severity, and clinical outcomes. Since the beginning of the COVID-19 global pandemic outbreak, the global research community has united in an unprecedented effort […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-09-25 03:17:302020-10-30 03:18:59Congenica Launches New Host Genetics Module to Advance COVID-19 Research
CALCIMEDICA ANNOUNCES THAT FDA HAS STRONGLY RECOMMENDED MOVING TO A BLINDED PLACEBO-CONTROLLED TRIAL WITH AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
/in CalcimedicaCALCIMEDICA APPOINTS ROBERT N. WILSON AS CO-CHAIRMAN OF THE BOARD OF DIRECTORS AND ERIC W. ROBERTS AS VICE CHAIRMAN
/in CalcimedicaArmata Pharmaceuticals Issues Letter to Shareholders
/in Armata PharmaceuticalsLink to Full Article MARINA DEL REY, Calif., Oct. 29, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today issued the following letter to shareholders. The letter has been made available to all existing shareholders with the Proxy for the […]
Congenica enhances the detection of inherited platelet disorders
/in CongenicaLink to Full Article A recent study from the University of Birmingham has shown that the Congenica platform demonstrated superior performance in identifying the genetic causes of platelet-related bleeding disorders [1]. Whole Exome Sequencing in combination with deep platelet phenotyping has been used in an earlier study (Genotyping and Phenotyping of Platelets, UK-GAPP) to identify pathogenic genetic […]
Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
/in Armata PharmaceuticalsLink to Full Article Appointment adds extensive expertise in the development of anti-infectives, including bacteriophage therapy to treat P. aeruginosa infections in cystic fibrosis patients MARINA DEL REY, Calif., Oct. 26, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat […]
FundamentalVR Expands into Ophthalmology
/in FundamentalVRLink to Full Article FundamentalVR launches full commercial ophthalmology capability BOSTON – October 20, 2020 – FundamentalVR, global pioneers in immersive VR surgical skills training and skills data analytics, today announced the expansion of its surgical specialty capabilities with the addition of ophthalmology. Powered by the company’s patented HapticVRTM technology architecture that mimics the physical cues of […]
HIKMA AND ARECOR EXPAND COLLABORATION WITH NEW AGREEMENT TO DEVELOP AND COMMERCIALISE READY-TO-ADMINISTER MEDICINE
/in ArecorLink to Full Article Adds ready-to-administer injectable product to companies’ existing partnership London and Cambridge, October 20, 2020 – Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into a new exclusive agreement to co-develop […]
Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections
/in Armata PharmaceuticalsLink to Full Article Upcoming study, to be known as “SWARM-P.a.,” is believed to be first FDA cleared, controlled clinical trial to evaluate a multiple phage-based mixture as a therapeutic candidate in Cystic Fibrosis patients MARINA DEL REY, Calif., Oct. 15, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused […]
Destiny Pharma Clinical Study Patient Recruitment Update
/in Destiny PharmaLink to Full Article 101 patients recruited in Phase 2b clinical study of lead asset XF-73 for the prevention of postsurgical infections Recruitment on track to complete by year-end and report results in Q1 2021 Brighton, United Kingdom – 12 October 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the […]
Congenica Launches New Host Genetics Module to Advance COVID-19 Research
/in CongenicaLink to Full Article Cambridge, United Kingdom – 22 September 2020 – Congenica has launched a new module for its genomic analysis platform that will accelerate research into the relationship between an individual’s genomic variation and COVID-19 susceptibility, severity, and clinical outcomes. Since the beginning of the COVID-19 global pandemic outbreak, the global research community has united in an unprecedented effort […]